1). Pileri SA., Milani M., Fraternali-Orcii G., Sabattini E. From the R.E.A.L classification to the upcoming WHO scheme: a step towards universal categorization of lymphoma entities? Ann Oncol. 1998. 9:607–12.
2). Cavalli F., Isaacson PG., Gascoyne RD., Zucca E. MALT lymphomas. Heamtology (Am Soc Hematol Educ Program). 2001. 241–58.
Article
3). Wotherspoon AC., Ortiz-Hidalgo C., Falzon MR., Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991. 338:1175–6.
4). Hyjek E., Smith WJ., Isaacson PG. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadnitis. Hum Pathol. 1988. 19:766–76.
5). Hyjek E., Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. Hum Pathol. 1988. 19:1315–26.
Article
6). Coiffier B. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Semin Oncol. 2003. 30(Suppl 2):21–7.
Article
7). Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. 2002. 29(Suppl 6):18–22.
Article
8). Hainsworth JD., Litchy S., Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002. 20:4261–7.
Article
9). Mclaughlin P., Grillo-Lopez AJ., Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998. 16:2825–33.
Article
10). Conconi A., Martinelli G., Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003. 102:2741–5.
Article
11). Martinelli G., Laszlo D., Ferreri A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005. 23:1979–83.
Article
12). Chong EA., Svoboda J., Cherian S, et al. Regression of pulmonary MALT lymphoma after treatment with rituximab. Leuk Lymphoma. 2005. 46:1383–6.
Article
13). Nuckel H., Meller D., Steuhl KP., Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol. 2004. 73:258–62.
14). Foxton MR., Knight L., Knisely AS, et al. Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pre-treated with rituximab. Liver Transpl. 2005. 11:839–42.
Article
15). Raderer M., Jager G., Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003. 65:306–10.
Article